Pharmacological HDAC inhibition impairs pancreatic β-cell function through an epigenome-wide reprogramming

oleh: Frédérik Oger, Maeva Moreno, Mehdi Derhourhi, Bryan Thiroux, Lionel Berberian, Cyril Bourouh, Emmanuelle Durand, Souhila Amanzougarene, Alaa Badreddine, Etienne Blanc, Olivier Molendi-Coste, Laurent Pineau, Gianni Pasquetti, Laure Rolland, Charlène Carney, Florine Bornaque, Emilie Courty, Céline Gheeraert, Jérôme Eeckhoute, David Dombrowicz, Julie Kerr-Conte, François Pattou, Bart Staels, Philippe Froguel, Amélie Bonnefond, Jean-Sébastien Annicotte

Format: Article
Diterbitkan: Elsevier 2023-07-01

Deskripsi

Summary: Histone deacetylases enzymes (HDACs) are chromatin modifiers that regulate gene expression through deacetylation of lysine residues within specific histone and non-histone proteins. A cell-specific gene expression pattern defines the identity of insulin-producing pancreatic β cells, yet molecular networks driving this transcriptional specificity are not fully understood. Here, we investigated the HDAC-dependent molecular mechanisms controlling pancreatic β-cell identity and function using the pan-HDAC inhibitor trichostatin A through chromatin immunoprecipitation assays and RNA sequencing experiments. We observed that TSA alters insulin secretion associated with β-cell specific transcriptome programming in both mouse and human β-cell lines, as well as on human pancreatic islets. We also demonstrated that this alternative β-cell transcriptional program in response to HDAC inhibition is related to an epigenome-wide remodeling at both promoters and enhancers. Our data indicate that HDAC activity could be required to protect against loss of β-cell identity with unsuitable expression of genes associated with alternative cell fates.